How do we use therapeutic drug monitoring to improve outcomes from severe infections in critically ill patients?
详细信息    查看全文
  • 作者：Gloria Wong (11)
    Fekade Bruck Sime (12) (13)
    Jeffrey Lipman (11) (14)
    Jason A Roberts (11) (12) (14)

    11. Burns Trauma and Critical Care Research Centre     ; The University of Queensland ; Brisbane ; Queensland ; Australia
    12. School of Pharmacy and Medical Sciences     ; University of South Australia ; Adelaide ; Australia
    13. Therapeutics Research Centre     ; Basil Hetzel Institute for Translational Health Research ; The Queen Elizabeth Hospital ; Adelaide ; Australia
    14. Royal Brisbane and Women鈥檚 Hospital     ; Level 3 Ned Hanlon Building ; Butterfield St ; Brisbane ; 4029 ; Queensland ; Australia
  • 关键词：TDM ; Antibiotic ; Pharmacokinetics ; Pharmacodynamics
  • 刊名：BMC Infectious Diseases
  • 出版年：2014
  • 出版时间：December 2014
  • 年：2014
  • 卷：14
  • 期：1
  • 全文大小：380 KB
  • 参考文献：1. Bellomo, R (2010) Mortality in severe sepsis: an inconvenient truth. Crit Care Resusc 12: pp. 6-8
    2. Boussekey, N, Cantrel, J, Dorchin Debrabant, L, Langlois, J, Devos, P, Meybeck, A, Chiche, A, Georges, H, Leroy, O (2010) Epidemiology, prognosis, and evolution of management of septic shock in a French intensive care unit: a five years survey. Crit Care Res Pract 2010: pp. 436427
    3. Melamed, A, Sorvillo, FJ (2009) The burden of sepsis-associated mortality in the United States from 1999 to 2005: an analysis of multiple-cause-of-death data. Crit Care 13: pp. R28 CrossRef
    4. Vincent, J-L, Rello, J, Marchall, JC, Silva, E, Anzueto, A, Martin, CD, Moreno, R, Lipman, J, Gomersall, CD, Sakr, Y, Reinhart, K (2009) International study of the prevalence and outcomes of infection in intensive care units. JAMA 302: pp. 2323-2329 ma.2009.1754" target="_blank" title="It opens in new window">CrossRef
    5. Roberts, J, Abdul Aziz, M, Lipman, J, Mouton, J, Vinks, A, Felton, T, Hope, W, Farkas, A, Neely, M, Schentag, J, Drusano, G, Frey, OR, Theuretzbacher, U, Kuti, JL (2014) Individualised antibiotic dosing for patients who are critically ill challenges and potential solutions. Lancet Inf Dis 14: pp. 498-509 CrossRef
    6. Taccone, FS, Laterre, P-F, Dugernier, T, Spapen, H, Delattre, IK, Wittebole, X, De Backer, D, Layeux, B, Wallemacq, P, Vincent, J-L, Jacobs, F (2010) Insufficient beta-lactam concentrations in the early phase of severe sepsis and septic shock. Crit Care 14: pp. R126 CrossRef
    7. Roberts, JA, Paul, SK, Akova, M, Bassetti, M, De Waele, JJ, Dimopoulos, G, Kaukonen, KM, Koulenti, D, Martin, C, Montravers, P, Rello, J, Rhodes, A, Starr, T, Wallis, SC, Lipman, J (2014) DALI: defining antibiotic levels in intensive care unit patients: are current beta-lactam antibiotic doses sufficient for critically ill patients?. Clin Infect Dis 58: pp. 1072-1083 CrossRef
    8. Rea, RS, Capitano, B, Bies, R, Bigos, KL, Smith, R, Lee, H (2008) Suboptimal aminoglycoside dosing in critically ill patients. Ther Drug Monit 30: pp. 674-681 CrossRef
    9. Roberts, JA, Taccone, FS, Udy, AA, Vincent, JL, Jacobs, F, Lipman, J (2011) Vancomycin dosing in critically ill patients: robust methods for improved continuous-infusion regimens. Antimicrob Agents Chemother 55: pp. 2704-2709 CrossRef
    10. van Zanten, AR, Polderman, KH, van Geijlswijk, IM, van der Meer, GY, Schouten, MA, Girbes, AR (2008) Ciprofloxacin pharmacokinetics in critically ill patients: a prospective cohort study. J Crit Care 23: pp. 422-430 CrossRef
    11. Swoboda, S, Ober, MC, Lichtenstern, C, Saleh, S, Schwenger, V, Sonntag, HG, Haefeli, WE, Hempel, G, Hoppe-Tichy, T, Weigand, MA (2010) Pharmacokinetics of linezolid in septic patients with and without extended dialysis. Eur J Clin Pharmacol 66: pp. 291-298 CrossRef
    12. Taccone, FS, Cotton, F, Roisin, S, Vincent, J-L, Jacobs, F (2012) Optimal meropenem concentrations to treat multidrug-resistant pseudomonas aeruginosa septic shock. Antimicrob Agents Chemother 56: pp. 2129-2131 CrossRef
    13. Tam, VH, Rogers, CA, Chang, KT, Weston, JS, Caeiro, JP, Garey, KW (2010) Impact of multidrug-resistant Pseudomonas aeruginosa bacteremia on patient outcomes. Antimicrob Agents Chemother 54: pp. 3717-3722 CrossRef
    14. Wegner, C, Hubner, NO, Gleich, S, Thalmaier, U, Kruger, CM, Kramer, A (2013) One-day point prevalence of emerging bacterial pathogens in a nationwide sample of 62 German hospitals in 2012 and comparison with the results of the one-day point prevalence of 2010. GMS Hyg Infect Control 8: pp. Doc12
    15. Kumar, A, Roberts, D, Wood, KE, Light, B, Parrillo, JE, Sharma, S, Suppes, R, Feinstein, D, Zanotti, S, Taiberg, L (2006) Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Crit Care Med 34: pp. 1589-1596 CrossRef
    16. Rybak, MJ, Lomaestro, BM, Rotschafer, JC, Moellering, RC, Craig, WA, Billeter, M, Dalovisio, JR, Levine, DP (2009) Vancomycin therapeutic guidelines: a summary of consensus recommendations from the infectious diseases Society of America, the American Society of Health-System Pharmacists, and the Society of Infectious Diseases Pharmacists. Clin Infect Dis 49: pp. 325-327 CrossRef
    17. Kullar, R, Davis, SL, Levine, DP, Rybak, MJ (2011) Impact of vancomycin exposure on outcomes in patients with methicillin-resistant Staphylococcus aureus bacteremia: support for consensus guidelines suggested targets. Clin Infect Dis 52: pp. 975-981 CrossRef
    18. McKinnon, PS, Paladino, JA, Schentag, JJ (2008) Evaluation of Area Under the Inhibitory Curve (AUIC) and Time Above the Minimum Inhibitory Concentration (T鈥?鈥塎IC) as predictors of outcome for cefepime and ceftazidime in serious bacterial infections. Int J Antimicrob Agents 31: pp. 345-351 micag.2007.12.009" target="_blank" title="It opens in new window">CrossRef
    19. van Lent-Evers, NA, Math么t, RA, Geus, WP, van Hout, BA, Vinks, AA (1999) Impact of goal-oriented and model-based clinical pharmacokinetic dosing of aminoglycosides on clinical outcome: a cost-effectiveness analysis. Ther Drug Monit 21: pp. 63-73 CrossRef
    20. Lacy, MK, Nicolau, DP, Nightingale, CH, Quintiliani, R (1998) The pharmacodynamics of aminoglycosides. Clin Infect Dis 27: pp. 23-27 CrossRef
    21. Forrest, A, Nix, DE, Ballow, CH, Goss, TF, Birmingham, MC, Schentag, JJ (1993) Pharmacodynamics of intravenous ciprofloxacin in seriously Ill patients. Antimicrob Agents Chemother 37: pp. 1073-1081 CrossRef
    22. Wong, G, Brinkman, A, Benefield, RJ, Carlier, M, De Waele, JJ, El Helali, N, Frey, O, Harbarth, S, Huttner, A, McWhinney, B, Misset, B, Pea, F, Preisenberger, J, Roberts, MS, Robertson, TA, Roehr, A, Sime, FB, Taccone, FS, Ungerer, JP, Lipman, J, Roberts, JA (2014) An international, multicentre survey of beta-lactam antibiotic therapeutic drug monitoring practice in intensive care units. J Antimicrob Chemother 69: pp. 1416-1423 CrossRef
    23. Roberts, JA, Norris, R, Paterson, DL, Martin, JH (2012) Therapeutic drug monitoring of antimicrobials. Br J Clin Pharmacol 73: pp. 27-36 CrossRef
    24. Dong, H, Wang, X, Dong, Y, Lei, J, Li, H, You, H, Wang, M, Xing, J, Sun, J, Zhu, H (2011) Clinical pharmacokinetic/pharmacodynamic profile of linezolid in severely ill intensive care unit patients. Int J Antimicrob Agents 38: pp. 296-300 micag.2011.05.007" target="_blank" title="It opens in new window">CrossRef
    25. Udy, AA, Roberts, JA, De Waele, JJ, Paterson, DL, Lipman, J (2012) What鈥檚 behind the failure of emerging antibiotics in the critically ill? Understanding the impact of altered pharmacokinetics and augmented renal clearance. Int J Antimicrob Agents 39: pp. 455-457 micag.2012.02.010" target="_blank" title="It opens in new window">CrossRef
    26. Udy, AA, Varghese, JM, Altukroni, M, Briscoe, S, McWhinney, B, Ungerer, J, Lipman, J, Roberts, JA (2012) Sub-therapeutic initial 尾-lactam concentrations in select critically ill patients. Chest 142: pp. 30-39 CrossRef
    27. Kielstein, JT, Burkhardt, O (2011) Dosing of antibiotics in critically ill patients undergoing renal replacement therapy. Curr Pharm Biotechnol 12: pp. 2015-2019 CrossRef
    28. Jamal, J-A, Economou, CJP, Lipman, J, Roberts, JA (2012) Improving antibiotic dosing in special situations in the ICU: burns, renal replacement therapy and extracorporeal membrane oxygenation. Curr Opin Crit Care 18: pp. 460-471 CrossRef
    29. Shekar, K, Fraser, JF, Smith, MT, Roberts, JA (2012) Pharmacokinetic changes in patients receiving extracorporeal membrane oxygenation. J Crit Care 27: pp. 741 CrossRef
    30. Choi, GYS, Gomersall, CD, Tian, Q, Joynt, GM, Freebairn, R, Lipman, J (2009) Principles of antibacterial dosing in continuous renal replacement therapy. Crit Care Med 37: pp. 2268-2282 CrossRef
    31. Tam, VH, Gamez, EA, Weston, JS, Gerard, LN, Larocco, MT, Caeiro, JP, Gentry, LO, Garey, KW (2008) Outcomes of bacteremia due to Pseudomonas aeruginosa with reduced susceptibility to piperacillin-tazobactam: implications on the appropriateness of the resistance breakpoint. Clin Infect Dis 46: pp. 862-867 CrossRef
    32. Weisenberg, SA, Morgan, DJ, Espinal-Witter, R, Larone, DH (2009) Clinical outcomes of patients with Klebsiella pneumoniae carbapenemase-producing K. pneumoniae after treatment with imipenem or meropenem. Diagn Microbiol Infect Dis 64: pp. 233-235 microbio.2009.02.004" target="_blank" title="It opens in new window">CrossRef
    33. Bhat, SV, Peleg, AY, Lodise, TPJ, Shutt, KA, Capitano, B, Potoski, BA, Paterson, DL (2007) Failure of current cefepime breakpoints to predict clinical outcomes of bacteremia caused by gram-negative organisms. Antimicrob Agents Chemother 51: pp. 4390-4395 CrossRef
    34. Vading, M, Samuelsen, O, Haldorsen, B, Sundsfjord, AS, Giske, CG (2011) Comparison of disk diffusion, Etest and VITEK2 for detection of carbapenemase-producing Klebsiella pneumoniae with the EUCAST and CLSI breakpoint systems. Clin Microbiol Infect 17: pp. 668-674 CrossRef
    35. Kitzis, M Antibiotic assay. In: Courvalin, P, Leclercq, R, Rice, LB eds. (2010) Antibiogram. ESKA Publishing, ASM Press, Portland, Oregon, pp. 75-88
    36. Sime, FB, Roberts, MS, Peake, SL, Lipman, J, Roberts, JA (2012) Does beta-lactam pharmacokinetic variability in critically ill patients justify therapeutic drug monitoring? A systematic review. Ann Intensive Care 2: pp. 35 CrossRef
    37. Tam, VH, McKinnon, PS, Akins, RL, Rybak, MJ, Drusano, GL (2002) Pharmacodynamics of cefepime in patients with Gram-negative infections. J Antimicrob Chemother 50: pp. 425-428 CrossRef
    38. Roberts, JA, Ulldemolins, M, Roberts, MS, McWhinney, B, Ungerer, J, Paterson, DL, Lipman, J (2010) Therapeutic drug monitoring of beta-lactams in critically ill patients: proof of concept. Int J Antimicrob Agents 36: pp. 332-339 micag.2010.06.008" target="_blank" title="It opens in new window">CrossRef
    39. Pea, F, Viale, P, Cojutti, P, Furlanut, M (2012) Dosing nomograms for attaining optimum concentrations of meropenem by continuous infusion in critically ill patients with severe gram-negative infections: a pharmacokinetics/pharmacodynamics-based approach. Antimicrob Agents Chemother 56: pp. 6343-6348 CrossRef
    40. Roberts, JA, Kirkpatrick, CMJ, Roberts, MS, Dalley, AJ, Lipman, J (2010) First-dose and steady-state population pharmacokinetics and pharmacodynamics of piperacillin by continuous or intermittent dosing in critically ill patients with sepsis. Int J Antimicrob Agents 35: pp. 156-163 micag.2009.10.008" target="_blank" title="It opens in new window">CrossRef
    41. Lee, GC, Liou, H, Yee, R, Quan, CF, Neldner, K (2012) Outcomes of extended-infusion piperacillin-tazobactam: a retrospective analysis of critically ill patients. Clin Ther 34: pp. 2297-2300 CrossRef
    42. Dulhunty, JM, Roberts, JA, Davis, JS, Webb, SA, Bellomo, R, Gomersall, C, Shirwadkar, C, Eastwood, GM, Myburgh, J, Paterson, DL, Starr, T, Udy, AA, Paul, SK, Lipman, J (2013) A protocol for a multicentre randomised controlled trial of continuous beta-lactam infusion compared with intermittent beta-lactam dosing in critically ill patients with severe sepsis: the BLING II study. Crit Care Resusc 15: pp. 179-185
    43. Pea, F, Cojutti, P, Sbrojavacca, R, Cadeo, B, Cristini, F, Bulfoni, A, Furlanut, M (2011) TDM-guided therapy with daptomycin and meropenem in a morbidly obese. Critically ill patient. Ann Pharmacother 45: pp. e37 CrossRef
    44. Lamoth, F, Buclin, T, Pascual, A, Vora, S, Bolay, S, Decosterd, LA, Calandra, T, Marchetti, O (2010) High cefepime plasma concentrations and neurological toxicity in febrile neutropenic patients with mild impairment of renal function. Antimicrob Agents Chemother 54: pp. 4360-4367 CrossRef
    45. Lonsdale, DO, Udy, AA, Roberts, JA, Lipman, J (2013) Antibacterial therapeutic drug monitoring in cerebrospinal fluid: difficulty in achieving adequate drug concentrations. J Neurosurg 118: pp. 297-301 CrossRef
    46. Chapuis, TM, Giannoni, E, Majcherczyk, PA, Chiolero, R, Schaller, M-D, Berger, MM, Bolay, S, Decosterd, LA, Bugnon, D, Moreillon, P (2010) Prospective monitoring of cefepime in intensive care unit adult patients. Crit Care 14: pp. R51 CrossRef
    47. Simon, N, Dussol, B, Sampol, E, Purgus, R, Brunet, P, Lacarelle, B, Berland, Y, Bruguerolle, B, Urien, S (2006) Population pharmacokinetics of ceftriaxone and pharmacodynamic considerations in haemodialysed patients. Clin Pharmacokinet 45: pp. 493-501 CrossRef
    48. Seyler, L, Cotton, F, Taccone, FS, De Backer, D, Macours, P, Vincent, J-L, Jacobs, F (2011) Recommended beta-lactam regimens are inadequate in septic patients treated with continuous renal replacement therapy. Crit Care 15: pp. R137 CrossRef
    49. Carlier, M, Stove, V, Roberts, JA, Van de Velde, E, De Waele, JJ, Verstraete, AG (2012) Quantification of seven beta-lactam antibiotics and two beta-lactamase inhibitors in human plasma using a validated UPLC-MS/MS method. Int J Antimicrob Agents 40: pp. 416-422 micag.2012.06.022" target="_blank" title="It opens in new window">CrossRef
    50. Ohmori, T, Suzuki, A, Niwa, T, Ushikoshi, H, Shirai, K, Yoshida, S, Ogura, S, Itoh, Y (2011) Simultaneous determination of eight beta-lactam antibiotics in human serum by liquid chromatography鈥搕andem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 879: pp. 1038-1042 mb.2011.03.001" target="_blank" title="It opens in new window">CrossRef
    51. Mendez, AS, Steppe, M, Schapoval, EE (2003) Validation of HPLC and UV spectrophotometric methods for the determination of meropenem in pharmaceutical dosage form. J Chromatogr B Analyt Technol Biomed Life Sci 33: pp. 947-954
    52. McWhinney, B, Wallis, SC, Hillister, T, Roberts, JA, Lipman, J, Ungerer, J (2010) Analysis of 12 beta-lactam antibiotics in human plasma by HPLC with ultraviolet detection. J Chromatogr B Analyt Technol Biomed Life Sci 878: pp. 2036-2043
    53. Briscoe, S, McWhinney, B, Lipman, J, Roberts, JA, Ungerer, JP (2012) A method for determining the free (unbound) concentration of ten beta-lactam antibiotics in human plasma using high performance liquid chromatography with ultraviolet detection. J Chromatogr B Analyt Technol Biomed Life Sci 907: pp. 178-184 mb.2012.09.016" target="_blank" title="It opens in new window">CrossRef
    54. Wong, G, Briscoe, S, Adnan, S, McWhinney, B, Ungerer, J, Lipman, J, Roberts, JA (2013) Protein binding of beta-lactam antibiotics in critically ill patients: can we successfully predict unbound concentrations?. Antimicrob Agents Chemother 57: pp. 6165-6170 CrossRef
    55. Farkas, A, Daroczi, G Individually Designed Optimum Dosing Strategies (ID-ODS): A Multi-Model Based Online Application to Individualize Antibiotic Dosing in Critically Ill Patients. In: Osten, WM, Lazar, EJ, Regan, BK eds. (2013) Proceedings of NewYork-Presbyterian Healthcare System Quality Symposium. The NewYork-Presbyterian, New Yorkpp. 240
    56. Barclay, ML, Kirkpatrick, CM, Begg, EJ (1999) Once daily aminoglycoside therapy. Is it less toxic than multiple daily doses and how should it be monitored?. Clin Pharmacokinet 36: pp. 89-98 CrossRef
    57. Nicolau, DP, Freeman, CD, Belliveau, PP, Nightingale, CH, Ross, JW, Quintiliani, R (1995) Experience with a once-daily aminoglycoside program administered to 2,184 adult patients. Antimicrob Agents Chemother 39: pp. 650-655 CrossRef
    58. Bartal, C, Danon, A, Schlaeffer, F, Reisenberg, K, Alkan, M, Smoliakov, R, Sidi, A, Almog, Y (2003) Pharmacokinetic dosing of aminoglycosides: a controlled trial. Am J Med 114: pp. 194-198 CrossRef
    59. Streetman, DS, Nafziger, AN, Destache, CJ, Bertino, AS (2001) Individualized pharmacokinetic monitoring results in less aminoglycoside-associated nephrotoxicity and fewer associated costs. Pharmacotherapy 21: pp. 443-451 CrossRef
    60. Sanchez-Alcaraz, A, Vargas, A, Quintana, MB, Rocher, A, Querol, JM, Poveda, JL, Hermenegildo, M (1998) Therapeutic drug monitoring of tobramycin: once-daily versus twice-daily dosage schedules. J Clin Pharm Ther 23: pp. 367-373 CrossRef
    61. Conil, JM, Georges, B, Ruiz, S, Rival, T, Seguin, T, Cougot, P, Fourcade, O, Pharmd, GH, Saivin, S (2011) Tobramycin disposition in ICU patients receiving a once daily regimen: population approach and dosage simulations. Br J Clin Pharmacol 71: pp. 61-71 CrossRef
    62. Taccone, FS, Laterre, PF, Spapen, H, Dugernier, T, Delattre, I, Layeux, B, De Backer, D, Wittebole, X, Wallemacq, P, Vincent, JL, Jacobs, F (2010) Revisiting the loading dose of amikacin for patients with severe sepsis and septic shock. Crit Care 14: pp. R53 CrossRef
    63. Conil, JM, Georges, B, Breden, A, Segonds, C, Lavit, M, Seguin, T, Coley, N, Samii, K, Chabanon, G, Houin, G, Saivin, S (2006) Increased amikacin dosage requirements in burn patients receiving a once-daily regimen. Int J Antimicrob Agents 28: pp. 226-230 micag.2006.04.015" target="_blank" title="It opens in new window">CrossRef
    64. Bracco, D, Landry, C, Dubois, MJ, Eggimann, P (2008) Pharmacokinetic variability of extended interval tobramycin in burn patients. Burns 34: pp. 791-796 burns.2007.11.003" target="_blank" title="It opens in new window">CrossRef
    65. Petejova, N, Zahalkova, J, Duricova, J, Kacirova, I, Brozmanova, H, Urbanek, K, Grundmann, M, Martinek, A (2012) Gentamicin pharmacokinetics during continuous venovenous hemofiltration in critically ill septic patients. J Chemother 24: pp. 107-112 CrossRef
    66. Boyer, A, Gruson, D, Bouchet, S, Clouzeau, B, Hoang-Nam, B, Vargas, F, Gilles, H, Molimard, M, Rogues, AM, Moore, N (2013) Aminoglycosides in septic shock: an overview, with specific consideration given to their nephrotoxic risk. Drug Saf 36: pp. 217-230 CrossRef
    67. Mueller, EW, Boucher, BA (2009) The use of extended-interval aminoglycoside dosing strategies for the treatment of moderate-to-severe infections encountered in critically ill surgical patients. Surg Infect (Larchmt) 10: pp. 563-570 CrossRef
    68. Prins, JM, Weverling, GJ, de Blok, K, van Ketel, RJ, Speelman, P (1996) Validation and nephrotoxicity of a simplified once-daily aminoglycoside dosing schedule and guidelines for monitoring therapy. Antimicrob Agents Chemother 40: pp. 2494-2499
    69. Wallace, AW, Jones, M, Bertino, JS (2002) Evaluation of four once-daily aminoglycoside dosing nomograms. Pharmacotherapy 22: pp. 1077-1083 CrossRef
    70. Botha, FJ, van der Bijl, P, Seifart, HI, Parkin, DP (1996) Fluctuation of the volume of distribution of amikacin and its effect on once-daily dosage and clearance in a seriously ill patient. Intensive Care Med 22: pp. 443-446 CrossRef
    71. Begg, EJ, Barclay, ML, Duffull, SB (1995) A suggested approach to once-daily aminoglycoside dosing. Br J Clin Pharmacol 39: pp. 605-609 CrossRef
    72. Fonge, H, Kaale, E, Govaerts, C, Desmet, K, Van Schepdael, A, Hoogmartens, J (2004) Bioanalysis of tobramycin for therapeutic drug monitoring by solid-phase extraction and capillary zone electrophoresis. J Chromatogr B Analyt Technol Biomed Life Sci 810: pp. 313-318 mb.2004.08.020" target="_blank" title="It opens in new window">CrossRef
    73. Dasgupta, A (2012) Advances in antibiotic measurement. Adv Clin Chem 56: pp. 75-104 CrossRef
    74. Avent, ML, Teoh, J, Lees, J, Eckert, KA, Kirkpatrick, CM (2011) Comparing 3 methods of monitoring gentamicin concentrations in patients with febrile neutropenia. Ther Drug Monit 33: pp. 592-601
    75. Delattre, IK, Musuamba, FT, Nyberg, J, Taccone, FS, Laterre, PF, Verbeeck, RK, Jacobs, F, Wallemacq, PE (2010) Population pharmacokinetic modeling and optimal sampling strategy for Bayesian estimation of amikacin exposure in critically ill septic patients. Ther Drug Monit 32: pp. 749-756 CrossRef
    76. Turnidge, J (2003) Pharmacodynamics and dosing of aminoglycosides. Infect Dis Clin 17: pp. 503-528 CrossRef
    77. Minejima, E, Choi, J, Beringer, P, Lou, M, Tse, E, Wong-Beringer, A (2011) Applying new diagnostic criteria for acute kidney injury to facilitate early identification of nephrotoxicity in vancomycin-treated patients. Antimicrob Agents Chemother 55: pp. 3278-3283 CrossRef
    78. Prabaker, KK, Tran, TP, Pratummas, T, Goetz, MB, Graber, CJ (2012) Elevated vancomycin trough is not associated with nephrotoxicity among inpatient veterans. J Hosp Med 7: pp. 91-97 m.946" target="_blank" title="It opens in new window">CrossRef
    79. Hidayat, LK, Hsu, DI, Quist, R, Shriner, KA, Wong-Beringer, A (2006) High-dose vancomycin therapy for methicillin-resistant Staphylococcus aureus infections: efficacy and toxicity. Arch Intern Med 166: pp. 2138-2144 CrossRef
    80. Jeffres, MN, Isakow, W, Doherty, JA, Micek, ST, Kollef, MH (2007) A retrospective analysis of possible renal toxicity associated with vancomycin in patients with health care-associated methicillin-resistant Staphylococcus aureus pneumonia. Clin Ther 29: pp. 1107-1115 CrossRef
    81. Lodise, TP, Lomaestro, B, Graves, J, Drusano, GL (2008) Larger vancomycin doses (at least four grams per day) are associated with an increased incidence of nephrotoxicity. Antimicrob Agents Chemother 52: pp. 1330-1336 CrossRef
    82. Bosso, JA, Nappi, J, Rudisill, C, Wellein, M, Bookstaver, PB, Swindler, J, Mauldin, PD (2011) Relationship between vancomycin trough concentrations and nephrotoxicity: a prospective multicenter trial. Antimicrob Agents Chemother 55: pp. 5475-5479 CrossRef
    83. Pritchard, L, Baker, C, Leggett, J, Sehdev, P, Brown, A, Bayley, KB (2010) Increasing vancomycin serum trough concentrations and incidence of nephrotoxicity. Am J Med 123: pp. 1143-1149 mjmed.2010.07.025" target="_blank" title="It opens in new window">CrossRef
    84. Hermsen, ED, Hanson, M, Sankaranarayanan, J, Stoner, JA, Florescu, MC, Rupp, ME (2010) Clinical outcomes and nephrotoxicity associated with vancomycin trough concentrations during treatment of deep-seated infections. Expert Opin Drug Saf 9: pp. 9-14 CrossRef
    85. van Hal, SJ, Paterson, DL, Lodise, TP (2013) Systematic review and meta-analysis of vancomycin-induced nephrotoxicity associated with dosing schedules that maintain troughs between 15 and 20 milligrams per liter. Antimicrob Agents Chemother 57: pp. 734-744 CrossRef
    86. Forouzesh, A, Moise, PA, Sakoulas, G (2009) Vancomycin ototoxicity: a reevaluation in an era of increasing doses. Antimicrob Agents Chemother 53: pp. 483-486 CrossRef
    87. Shields, RK, Martello, JL, Potoski, BA (2009) Is vancomycin ototoxicity a significant risk?. Antimicrob Agents Chemother 53: pp. 4572 CrossRef
    88. Jeffres, MN, Isakow, W, Doherty, JA, McKinnon, PS, Ritchie, DJ, Micek, ST, Kollef, MH (2006) Predictors of mortality for methicillin-resistant Staphylococcus aureus health-care-associated pneumonia: specific evaluation of vancomycin pharmacokinetic indices. Chest 130: pp. 947-955 CrossRef
    89. Iwamoto, T, Kagawa, Y, Kojima, M (2003) Clinical efficacy of therapeutic drug monitoring in patients receiving vancomycin. Biol Pharm Bull 26: pp. 876-879 CrossRef
    90. Cheong, JY, Makmor-Bakry, M, Lau, CL, Abdul Rahman, R (2012) The relationship between trough concentration of vancomycin and effect on methicillin-resistant Staphylococcus aureus in critically ill patients. S Afr Med J 102: pp. 616-619
    91. Ye, ZK, Tang, HL, Zhai, SD (2013) Benefits of therapeutic drug monitoring of vancomycin: a systematic review and meta-analysis. PLoS One 8: pp. e77169 CrossRef
    92. Sakoulas, G, Gold, HS, Cohen, RA, Venkataraman, L, Moellering, RC, Eliopoulos, GM (2006) Effects of prolonged vancomycin administration on methicillin-resistant Staphylococcus aureus (MRSA) in a patient with recurrent bacteraemia. J Antimicrob Chemother 57: pp. 699-704 CrossRef
    93. Howden, BP, Ward, PB, Charles, PG, Korman, TM, Fuller, A, du Cros, P, Grabsch, EA, Roberts, SA, Robson, J, Read, K, Bak, N, Hurley, J, Johnson, PD, Morris, AJ, Mayall, BC, Grayson, ML (2004) Treatment outcomes for serious infections caused by methicillin-resistant Staphylococcus aureus with reduced vancomycin susceptibility. Clin Infect Dis 38: pp. 521-528 CrossRef
    94. Moellering, RC (1994) Monitoring serum vancomycin levels: climbing the mountain because it is there?. Clin Infect Dis 18: pp. 544-546 CrossRef
    95. Rybak, M, Lomaestro, B, Rotschafer, JC, Moellering, R, Craig, W, Billeter, M, Dalovisio, JR, Levine, DP (2009) Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. Am J Health Syst Pharm 66: pp. 82-98 CrossRef
    96. Potoski, BA, Paterson, DL (2007) Appropriate pharmacokinetic index for outcome in Staphylococcus aureus pneumonia. Chest 132: pp. 1101-1102 CrossRef
    97. Morrison, AP, Melanson, SE, Carty, MG, Bates, DW, Szumita, PM, Tanasijevic, MJ (2012) What proportion of vancomycin trough levels are drawn too early? Frequency and impact on clinical actions. Am J Clin Pathol 137: pp. 472-478 CrossRef
    98. Takahashi, Y, Takesue, Y, Takubo, S, Ishihara, M, Nakajima, K, Tsuchida, T, Ikeuchi, H, Uchino, M (2013) Preferable timing of therapeutic drug monitoring in patients with impaired renal function treated with once-daily administration of vancomycin. J Infect Chemother 19: pp. 709-716 CrossRef
    99. Tobin, CM, Darville, JM, Thomson, AH, Sweeney, G, Wilson, JF, MacGowan, AP, White, LO (2002) Vancomycin therapeutic drug monitoring: is there a consensus view? The results of a UK National External Quality Assessment Scheme (UK NEQAS) for antibiotic assays questionnaire. J Antimicrob Chemother 50: pp. 713-718 CrossRef
    100. Matsumoto, K, Takesue, Y, Ohmagari, N, Mochizuki, T, Mikamo, H, Seki, M, Takakura, S, Tokimatsu, I, Takahashi, Y, Kasahara, K, Okada, K, Igarashi, M, Kobayashi, M, Hamada, Y, Kimura, M, Nishi, Y, Tanigawara, Y, Kimura, T (2013) Practice guidelines for therapeutic drug monitoring of vancomycin: a consensus review of the Japanese Society of Chemotherapy and the Japanese Society of Therapeutic Drug Monitoring. J Infect Chemother 19: pp. 365-380 CrossRef
    101. Wilson, JF, Davis, AC, Tobin, CM (2003) Evaluation of commercial assays for vancomycin and aminoglycosides in serum: a comparison of accuracy and precision based on external quality assessment. J Antimicrob Chemother 52: pp. 78-82 CrossRef
    102. Murphy, JE, Gillespie, DE, Bateman, CV (2006) Predictability of vancomycin trough concentrations using seven approaches for estimating pharmacokinetic parameters. Am J Health Syst Pharm 63: pp. 2365-2370 CrossRef
    103. DeRyke, CA, Alexander, DP (2009) Optimizing vancomycin dosing through pharmacodynamic assessment targeting area under the concentration-time curve/minimum inhibitory concentration. Hosp Pharm 44: pp. 751-765 CrossRef
    104. Pea, F, Bertolissi, M, Di Silvestre, A, Poz, D, Giordano, F, Furlanut, M (2002) TDM coupled with Bayesian forecasting should be considered an invaluable tool for optimizing vancomycin daily exposure in unstable critically ill patients. Int J Antimicrob Agents 20: pp. 326-332 CrossRef
    105. Avent, ML, Vaska, VL, Rogers, BA, Cheng, AC, van Hal, SJ, Holmes, NE, Howden, BP, Paterson, DL (2013) Vancomycin therapeutics and monitoring: a contemporary approach. Intern Med J 43: pp. 110-119 mj.12036" target="_blank" title="It opens in new window">CrossRef
    106. Man, SS, Carr, RR, Ensom, MH (2010) Comparison of continuous and intermittent IV infusion of vancomycin: systematic review. Can J Hosp Pharm 63: pp. 373-381
    107. James, JK, Palmer, SM, Levine, DP, Rybak, MJ (1996) Comparison of conventional dosing versus continuous-infusion vancomycin therapy for patients with suspected or documented gram-positive infections. Antimicrob Agents Chemother 40: pp. 696-700
    108. Wysocki, M, Delatour, F, Faurisson, F, Rauss, A, Pean, Y, Misset, B, Thomas, F, Timsit, JF, Similowski, T, Mentec, H, Mier, L, Dreyfuss, D (2001) Continuous versus intermittent infusion of vancomycin in severe Staphylococcal infections: prospective multicenter randomized study. Antimicrob Agents Chemother 45: pp. 2460-2467 CrossRef
    109. DiMondi, VP, Rafferty, K (2013) Review of continuous-infusion vancomycin. Ann Pharmacother 47: pp. 219-227 CrossRef
    110. Panday, PN, Sturkenboom, M (2009) Continuous infusion of vancomycin less effective and safe than intermittent infusion, based on pharmacodynamic and pharmacokinetic principles. Clin Infect Dis 49: pp. 1964-1965 CrossRef
    111. Jeurissen, A, Sluyts, I, Rutsaert, R (2011) A higher dose of vancomycin in continuous infusion is needed in critically ill patients. Int J Antimicrob Agents 37: pp. 75-77 micag.2010.09.004" target="_blank" title="It opens in new window">CrossRef
    112. De Waele, JJ, Danneels, I, Depuydt, P, Decruyenaere, J, Bourgeois, M, Hoste, E (2013) Factors associated with inadequate early vancomycin levels in critically ill patients treated with continuous infusion. Int J Antimicrob Agents 41: pp. 434-438 micag.2012.12.015" target="_blank" title="It opens in new window">CrossRef
    113. Saugel, B, Nowack, MC, Hapfelmeier, A, Umgelter, A, Schultheiss, C, Thies, P, Phillip, V, Eyer, F, Schmid, RM, Huber, W (2013) Continuous intravenous administration of vancomycin in medical intensive care unit patients. J Crit Care 28: pp. 9-13 CrossRef
    114. Ampe, E, Delaere, B, Hecq, JD, Tulkens, PM, Glupczynski, Y (2013) Implementation of a protocol for administration of vancomycin by continuous infusion: pharmacokinetic, pharmacodynamic and toxicological aspects. Int J Antimicrob Agents 41: pp. 439-446 micag.2013.01.009" target="_blank" title="It opens in new window">CrossRef
    115. Cataldo, MA, Tacconelli, E, Grilli, E, Pea, F, Petrosillo, N (2012) Continuous versus intermittent infusion of vancomycin for the treatment of Gram-positive infections: systematic review and meta-analysis. J Antimicrob Chemother 67: pp. 17-24 CrossRef
    116. Stalker, DJ, Jungbluth, GL (2003) Clinical pharmacokinetics of linezolid, a novel oxazolidinone antibacterial. Clin Pharmacokinet 42: pp. 1129-1140 CrossRef
    117. Tsuji, Y, Hiraki, Y, Mizoguchi, A, Hayashi, W, Kamohara, R, Kamimura, H, Karube, Y (2008) Pharmacokinetics of repeated dosing of linezolid in a hemodialysis patient with chronic renal failure. J Infect Chemother 14: pp. 156-160 CrossRef
    118. Tsuji, Y, Hiraki, Y, Matsumoto, K, Mizoguchi, A, Kobayashi, T, Sadoh, S, Morita, K, Kamimura, H, Karube, Y (2011) Thrombocytopenia and anemia caused by a persistent high linezolid concentration in patients with renal dysfunction. J Infect Chemother 17: pp. 70-75 CrossRef
    119. Matsumoto, K, Takeshita, A, Ikawa, K, Shigemi, A, Yaji, K, Shimodozono, Y, Morikawa, N, Takeda, Y, Yamada, K (2010) Higher linezolid exposure and higher frequency of thrombocytopenia in patients with renal dysfunction. Int J Antimicrob Agents 36: pp. 179-181 micag.2010.02.019" target="_blank" title="It opens in new window">CrossRef
    120. Nukui, Y, Hatakeyama, S, Okamoto, K, Yamamoto, T, Hisaka, A, Suzuki, H, Yata, N, Yotsuyanagi, H, Moriya, K (2013) High plasma linezolid concentration and impaired renal function affect development of linezolid-induced thrombocytopenia. J Antimicrob Chemother 68: pp. 2128-2133 CrossRef
    121. Sousa, R, Lopez, R, Martinez-Pastor, JC, Cervera, C, Bori, G, Garcia-Ramiro, S, Mensa, J, Soriano, A (2011) Usefulness of monitoring linezolid trough serum concentration in prolonged treatments. Rev Esp Quimioter 24: pp. 151-153
    122. Pea, F, Furlanut, M, Cojutti, P, Cristini, F, Zamparini, E, Franceschi, L, Viale, P (2010) Therapeutic drug monitoring of linezolid: a retrospective monocentric analysis. Antimicrob Agents Chemother 54: pp. 4605-4610 CrossRef
    123. Hallam, MJ, Allen, JM, James, SE, Donaldson, PM, Davies, JG, Hanlon, GW, Dheansa, BS (2010) Potential subtherapeutic linezolid and meropenem antibiotic concentrations in a patient with severe burns and sepsis. J Burn Care Res 31: pp. 207-209 CrossRef
    124. Lovering, AM, Le Floch, R, Hovsepian, L, Stephanazzi, J, Bret, P, Birraux, G, Vinsonneau, C (2009) Pharmacokinetic evaluation of linezolid in patients with major thermal injuries. J Antimicrob Chemother 63: pp. 553-559 CrossRef
    125. Pea, F, Scudeller, L, Lugano, M, Baccarani, U, Pavan, F, Tavio, M, Furlanut, M, Rocca, GD, Bresadola, F, Viale, P (2006) Hyperlactacidemia potentially due to linezolid overexposure in a liver transplant recipient. Clin Infect Dis 42: pp. 434-435 CrossRef
    126. Pea, F, Viale, P, Lugano, M, Pavan, F, Scudeller, L, Della Rocca, G, Furlanut, M (2004) Linezolid disposition after standard dosages in critically ill patients undergoing continuous venovenous hemofiltration: a report of 2 cases. Am J Kidney Dis 44: pp. 1097-1102 CrossRef
    127. Pea, F, Cojutti, P, Pagotto, A, Cristini, F, Furlanut, M, Viale, P (2012) Successful long-term treatment of cerebral nocardiosis with unexpectedly low doses of linezolid in an immunocompromised patient receiving complex polytherapy. Antimicrob Agents Chemother 56: pp. 3438-3440 CrossRef
    128. Polillo, M, Tascini, C, Lastella, M, Malacarne, P, Ciofi, L, Viaggi, B, Bocci, G, Menichetti, F, Danesi, R, Del Tacca, M, Di Paolo, A (2010) A rapid high-performance liquid chromatography method to measure linezolid and daptomycin concentrations in human plasma. Ther Drug Monit 32: pp. 200-205
    129. Alffenaar, JW, Kosterink, JG, van Altena, R, van der Werf, TS, Uges, DR, Proost, JH (2010) Limited sampling strategies for therapeutic drug monitoring of linezolid in patients with multidrug-resistant tuberculosis. Ther Drug Monit 32: pp. 97-101 CrossRef
    130. Cattaneo, D, Baldelli, S, Conti, F, Cozzi, V, Clementi, E (2010) Determination of linezolid in human plasma by high-performance liquid chromatography with ultraviolet detection. Ther Drug Monit 32: pp. 520-524 CrossRef
    131. Baietto, L, D鈥橝volio, A, Ariaudo, A, Corcione, S, Simiele, M, Cusato, J, Urbino, R, Di Perri, G, Ranieri, VM, De Rosa, FG (2013) Development and validation of a new UPLC-PDA method to quantify linezolid in plasma and in dried plasma spots. J Chromatogr B Analyt Technol Biomed Life Sci 936: pp. 42-47 mb.2013.08.003" target="_blank" title="It opens in new window">CrossRef
    132. Vu, DH, Bolhuis, MS, Koster, RA, Greijdanus, B, de Lange, WC, van Altena, R, Brouwers, JR, Uges, DR, Alffenaar, JW (2012) Dried blood spot analysis for therapeutic drug monitoring of linezolid in patients with multidrug-resistant tuberculosis. Antimicrob Agents Chemother 56: pp. 5758-5763 CrossRef
    133. Bolhuis, MS, van Altena, R, van Hateren, K, de Lange, WC, Greijdanus, B, Uges, DR, Kosterink, JG, van der Werf, TS, Alffenaar, JW (2013) Clinical validation of the analysis of linezolid and clarithromycin in oral fluid of patients with multidrug-resistant tuberculosis. Antimicrob Agents Chemother 57: pp. 3676-3680 CrossRef
    134. Kontou, P, Chatzika, K, Pitsiou, G, Stanopoulos, I, Argyropoulou-Pataka, P, Kioumis, I (2011) Pharmacokinetics of ciprofloxacin and its penetration into bronchial secretions of mechanically ventilated patients with chronic obstructive pulmonary disease. Antimicrob Agents Chemother 55: pp. 4149-4153 CrossRef
    135. Fish, DN, Piscitelli, SC, Danziger, LH (1995) Development of resistance during antimicrobial therapy: a review of antibiotic classes and patient characteristics in 173 studies. Pharmacotherapy 15: pp. 279-291
    136. Gasser, TC, Ebert, SC, Graversen, PH, Madsen, PO (1987) Ciprofloxacin pharmacokinetics in patients with normal and impaired renal function. Antimicrob Agents Chemother 31: pp. 709-712 CrossRef
    137. Pea, F, Poz, D, Viale, P, Pavan, F, Furlanut, M (2006) Which reliable pharmacodynamic breakpoint should be advised for ciprofloxacin monotherapy in the hospital setting? A TDM-based retrospective perspective. J Antimicrob Chemother 58: pp. 380-386 CrossRef
    138. Jones, EM, McMullin, CM, Hedges, AJ, Lovering, AM, White, LO, Reeves, DS, MacGowan, AP (1997) The pharmacokinetics of intravenous ciprofloxacin 400聽mg 12 hourly in patients with severe sepsis: the effect of renal function and intra-abdominal disease. J Antimicrob Chemother 40: pp. 121-124 CrossRef
    139. Gous, A, Lipman, J, Scribante, J, Tshukutsoane, S, Hon, H, Pinder, M, Mathivha, R, Verhoef, L, Stass, H (2005) Fluid shifts have no influence on ciprofloxacin pharmacokinetics in intensive care patients with intra-abdominal sepsis. Int J Antimicrob Agents 26: pp. 50-55 micag.2005.04.005" target="_blank" title="It opens in new window">CrossRef
    140. Fish, DN, Bainbridge, JL, Peloquin, CA (1995) Variable disposition of ciprofloxacin in critically ill patients undergoing continuous arteriovenous hemodiafiltration. Pharmacotherapy 15: pp. 236-245
    141. Roberts, DM, Roberts, JA, Roberts, MS, Liu, X, Nair, P, Cole, L, Lipman, J, Bellomo, R (2012) Variability of antibiotic concentrations in critically ill patients receiving continuous renal replacement therapy: a multicentre pharmacokinetic study. Crit Care Med 40: pp. 1523-1528 CrossRef
    142. van Geijlswijk, IM, van Zanten, AR, van der Meer, YG (2006) Reliable new high-performance liquid chromatographic method for the determination of ciprofloxacin in human serum. Ther Drug Monit 28: pp. 278-281 CrossRef
    143. Sousa, J, Alves, G, Campos, G, Fortuna, A, Falcao, A (2013) First liquid chromatography method for the simultaneous determination of levofloxacin, pazufloxacin, gatifloxacin, moxifloxacin and trovafloxacin in human plasma. J Chromatogr B Analyt Technol Biomed Life Sci 930: pp. 104-111 mb.2013.04.036" target="_blank" title="It opens in new window">CrossRef
    144. Al-Ghazawi, M, AbuRuz, S (2010) Determination of ciprofloxacin in dried blood spots for therapeutic drug monitoring. Chromatographia 71: pp. 999-1005 CrossRef
    145. Sun, HW, He, P, Lv, YK, Liang, SX (2007) Effective separation and simultaneous determination of seven fluoroquinolones by capillary electrophoresis with diode-array detector. J Chromatogr B Analyt Technol Biomed Life Sci 852: pp. 145-151 mb.2007.01.016" target="_blank" title="It opens in new window">CrossRef
    146. Zeng, H-J, Yang, R, Liu, B, Lei, L-F, Li, J-J, Qu, L-B (2012) Simple and sensitive determination of sparfloxacin in pharmaceuticals and biological samples by immunoassay. J Pharmaceutical Analysis 2: pp. 214-219 CrossRef
    147. Wenisch, JM, Meyer, B, Fuhrmann, V, Saria, K, Zuba, C, Dittrich, P, Thalhammer, F (2012) Multiple-dose pharmacokinetics of daptomycin during continuous venovenous haemodiafiltration. J Antimicrob Chemother 67: pp. 977-983 CrossRef
    148. Falcone, M, Russo, A, Venditti, M, Novelli, A, Pai, MP (2013) Considerations for higher doses of daptomycin in critically ill patients with methicillin-resistant Staphylococcus aureus bacteremia. Clin Infect Dis 57: pp. 1568-1576 CrossRef
    149. Pea, F, Crapis, M, Cojutti, P, Bassetti, M (2014) Daptomycin underexposure in a young intravenous drug user who was affected by life-threatening Staphylococcus aureus-complicated skin and soft tissue infection associated with bacteraemia. Infection 42: pp. 207-210 CrossRef
    150. Bhavnani, SM, Rubino, CM, Ambrose, PG, Drusano, GL (2010) Daptomycin exposure and the probability of elevations in the creatine phosphokinase level: data from a randomized trial of patients with bacteremia and endocarditis. Clin Infect Dis 50: pp. 1568-1574 CrossRef
    151. Falcone, M, Russo, A, Cassetta, MI, Lappa, A, Tritapepe, L, d鈥橢ttorre, G, Fallani, S, Novelli, A, Venditti, M (2013) Variability of pharmacokinetic parameters in patients receiving different dosages of daptomycin: is therapeutic drug monitoring necessary?. J Infect Chemother 19: pp. 732-739 CrossRef
    152. Safdar, N, Andes, D, Craig, WA (2004) In vivo pharmacodynamic activity of daptomycin. Antimicrob Agents Chemother 48: pp. 63-68 CrossRef
    153. Bazoti, FN, Gikas, E, Skoutelis, A, Tsarbopoulos, A (2011) Development and validation of an ultra performance liquid chromatography-tandem mass spectrometry method for the quantification of daptomycin in human plasma. J Pharm Biomed Anal 56: pp. 78-85 CrossRef
    154. Craig, WA (1995) Interrelationship between pharmacokinetics and pharmacodynamics in determining dosage regimens for broad-spectrum cephalosporins. Diagn Microbiol Infect Dis 22: pp. 89-96 CrossRef
    155. Li, C, Du, X, Kuti, JL, Nicolau, DP (2007) Clinical pharmacodynamics of meropenem in patients with lower respiratory tract infections. Antimicrob Agents Chemother 51: pp. 1725-1730 CrossRef
    156. Rayner, CR, Forrest, A, Meagher, AK, Birmingham, MC, Schentag, JJ (2003) Clinical pharmacodynamics of linezolid in seriously ill patients treated in a compassionate use programme. Clinical Pharmacokinet 42: pp. 1411-1423 CrossRef
    157. Cattaneo, D, Orlando, G, Cozzi, V, Cordier, L, Baldelli, S, Merli, S, Fucile, S, Gulisano, C, Rizzardini, G, Clementi, E (2013) Linezolid plasma concentrations and occurrence of drug-related haematological toxicity in patients with gram-positive infections. Int J Antimicrob Agents 41: pp. 586-589 micag.2013.02.020" target="_blank" title="It opens in new window">CrossRef
    158. Pea, F, Viale, P, Cojutti, P, Del Pin, B, Zamparini, E, Furlanut, M (2012) Therapeutic drug monitoring may improve safety outcomes of long-term treatment with linezolid in adult patients. J Antimicrob Chemother 67: pp. 2034-2042 CrossRef
    159. Schentag, JJ (1999) Antimicrobial action and pharmacokinetics/pharmacodynamics: the use of AUIC to improve efficacy and avoid resistance. J Chemother 11: pp. 426-439 CrossRef
    160. Zelenitsky, SA, Ariano, RE (2010) Support for higher ciprofloxacin AUC 24/MIC targets in treating Enterobacteriaceae bloodstream infection. J Antimicrob Chemother 65: pp. 1725-1732 CrossRef
    161. Scaglione, F (2002) Can PK/PD be used in everyday clinical practice. Int J Antimicrob Agents 19: pp. 349-353 CrossRef
    162. Rodvold, KA, Neuhauser, M (2001) Pharmacokinetics and pharmacodynamics of fluoroquinolones. Pharmacotherapy 21: pp. 233S-252S CrossRef
    163. Moore, RD, Lietman, PS, Smith, CR (1987) Clinical response to aminoglycoside therapy: importance of the ratio of peak concentration to minimal inhibitory concentration. J Infect Dis 155: pp. 93-99 CrossRef
    164. The pre-publication history for this paper can be accessed here:medcentral.com/1471-2334/14/288/prepub" class="a-plus-plus">http://www.biomedcentral.com/1471-2334/14/288/prepub
  • 刊物主题：Infectious Diseases; Parasitology; Medical Microbiology; Tropical Medicine; Internal Medicine;
  • 出版者：BioMed Central
  • ISSN：1471-2334
文摘
High mortality and morbidity rates associated with severe infections in the critically ill continue to be a significant issue for the healthcare system. In view of the diverse and unique pharmacokinetic profile of drugs in this patient population, there is increasing use of therapeutic drug monitoring (TDM) in attempt to optimize the exposure of antibiotics, improve clinical outcome and minimize the emergence of antibiotic resistance. Despite this, a beneficial clinical outcome for TDM of antibiotics has only been demonstrated for aminoglycosides in a general hospital patient population. Clinical outcome studies for other antibiotics remain elusive. Further, there is significant variability among institutions with respect to the practice of TDM including the selection of patients, sampling time for concentration monitoring, methodologies of antibiotic assay, selection of PK/PD targets as well as dose optimisation strategies. The aim of this paper is to review the available evidence relating to practices of antibiotic TDM, and describe how TDM can be applied to potentially improve outcomes from severe infections in the critically ill.

© 2004-2018 中国地质图书馆版权所有 京ICP备05064691号 京公网安备11010802017129号

地址：北京市海淀区学院路29号 邮编：100083

电话：办公室：(+86 10)66554848；文献借阅、咨询服务、科技查新：66554700